Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03726762
Other study ID # ND-307
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2015
Est. completion date June 2017

Study information

Verified date October 2018
Source Novindiet Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the present study aimed to follow up our participants in order to consider the changes in weight and anthropometric measurements after the 12-month weight maintenance as well as the total of 18 months, consisting of the previously described 24 weeks active weight loss and a further 53 weeks weight maintenance. The secondary outcome was to compare the abdominal adiposity, carbohydrate, and lipid metabolism during these periods.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date June 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Diabetic female patient with 6.5<H1AC<7.2.

- Monotherapy with Metformin.

- 18-45 years of age.

- Body mass index (BMI) between 27-35 kg/ m².

- Consume DBs regularly during their habitual diet.

- Must be able to have moderate exercise.

- Must be interested to have weight loss.

Exclusion Criteria:

- Participating in a research project involving weight loss or physical activity in the previous six months.

- Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months.

- Taking medication that could affect metabolism or change body weight.

- Report heart problems, chest pain, and cancer within the last five years.

- Unwilling to change intake of beverages during the study period.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
DBs at the end of the main meal + weight control program
Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
Water at the end of the main meal+ weight control program
Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.

Locations

Country Name City State
Iran, Islamic Republic of NovinDiet Clinic Tehran

Sponsors (3)

Lead Sponsor Collaborator
Novindiet Clinic Tehran University of Medical Sciences, University of Nottingham

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weight loss 77 weeks
Secondary Fasting plasma glucose 77 weeks
Secondary Insulin resistance (HOMA) 77 weeks
Secondary Lipid profiles 77 weeks
Secondary Waist circumference 77 weeks
Secondary BMI 77 Weeks
Secondary HA1C 77 Weeks
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A